TLSA — Tiziana Life Sciences Share News
0.000.00%
Last trade - 00:00- $137.84m
- $134.28m
Brief: Tiziana Life Sciences Regains Compliance With Nasdaq Listing Minimum Bid Price Rule
Brief: Tiziana Life Sciences Granted FDA Fast Track Designation
Brief: FDA Accepts Tiziana Life Sciences Fast Track Designation Submission For Treatment Of Multiple Sclerosis
Brief: Tiziana Life Sciences Applied For FDA Orphan Drug Designation Of Foralumab For na-SPMS
Brief: Tiziana Life Sciences Submits Grant Application to ALS Association to Fund Clinical Trial of Intranasal Foralumab
Brief: Tiziana Life Sciences Files For Orphan Drug Designation For Intranasal Foralumab
Brief: Tiziana Life Sciences Announces Updated Clinical And Pet Scan Findings For Intranasal Foralumab
Brief: Tiziana Life Sciences Files New Patent Application for Combination Therapy of Anti-CD3 With GLP-1 Receptor Agonist
Brief: Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab in Multiple Sclerosis
Brief: Tiziana Life Sciences Announces Positive Six-Month Clinical Results In Multiple Sclerosis Patients Treated With Intranasal Foralumab
Brief: Tiziana Announces Positive Qualitative Six-Month Pet Scan Results
Brief: Tiziana Life Sciences Initiates Multi-Center Phase 2A Clinical Trial Of Intranasal Foralumab
Tiziana gains on FDA clearance to start Alzheimer's treatment study
Brief: Tiziana Life Sciences Announces FDA Ind Clearance Of Intranasal Foralumab For The Treatment Of Alzheimer’S Disease
Brief: Tiziana Life Sciences Receives Nasdaq Deficiency Notice
Brief: Tiziana Life Sciences Announces Reduction In Microglial Activation In A Total Of 5 Out Of 6 Intranasal Foralumab Expanded Access Patients With Non-Active Secondary Progressive Multiple Sclerosis
Intranasal Anti-Cd3 Mab Treatment Showed A Reduction In Intracerebral Hemorrhage Injury Severity
Brief: Tiziana Life Sciences Regains Compliance With Nasdaq Listing Minimum Bid Price Rule
Brief: Tiziana Life Sciences To File Alzheimer’S Ind For Intranasal Foralumab In Q2 2023